StockData
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc. (AMRX) stock

AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3063% above fair value
$21.12−0.11 (-0.52%)

Close on Nov 17, 2026Market cap $6.74BP/E 43.1Yield –

Amneal Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Amneal Pharmaceuticals's pe ratio was 44.3× on Nov 11, 2026, against 626.0× a year earlier. Over the last 3 years it ranged from 8.8× to 956.0×, with a median of 56.5×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202644.3×−585.7
2025Dec 31, 2025630.0×+540.8
2024Jan 31, 202489.2×−12.0
2023Dec 29, 2023101.2×−75.8
2022Jul 29, 2022177.0×+123.8
2021Dec 31, 202153.2×+42.1
2020Dec 31, 202011.1×–

More Amneal Pharmaceuticals figures

See a number that looks wrong?